David Egilman, Doctor Who Took On Drug Companies, Dies at 71
His testimony as an expert witness in some 600 trials helped plaintiffs win billions of dollars in cases involving malfeasance by pharmaceutical makers. (Source: NYT Health)
Source: NYT Health - April 15, 2024 Category: Consumer Health News Authors: Clay Risen Tags: Egilman, David Deaths (Obituaries) Drugs (Pharmaceuticals) Brown University Doctors Ethics and Official Misconduct Witnesses Merck & Company Inc Vioxx (Drug) Suits and Litigation (Civil) Source Type: news
Will the Headache Field Embrace Rofecoxib (Vioxx)? Will the Headache Field Embrace Rofecoxib (Vioxx)?
Experts discuss the history of rofecoxib, including its market withdrawal and subsequent resurrection. The once-bestselling painkiller known as Vioxx is now proceeding to a phase 3 trial for migraine.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2022 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Big Pharma Is Hijacking the Information Doctors Need Most
Back in 1982, when I first began my career as a family practitioner in a small town of Boston, I was confident that the care I’d provide would be as effective as the care patients receive anywhere in the world. At the time, the death rate for Americans was lower than that of comparable countries, resulting in 128,000 fewer deaths annually. Although healthcare was expensive—costing 2.3% more of our GDP than the average of 11 other wealthy countries—the rapid growth of HMOs and managed care plans promised to make our healthcare even more effective and efficient.
Over the ensuing four decades, however, the o...
Source: TIME: Health - April 28, 2022 Category: Consumer Health News Authors: John Abramson Tags: Uncategorized Source Type: news
Post-market safety communication for protection of public health: a comparison of regulatory policy in Australia, Canada, the European Union, and the United States - Bhasale AL, Sarpatwari A, De Bruin ML, Lexchin J, Lopert R, Bahri P, Mintzes BJ.
In the wake of the rofecoxib withdrawal, regulators worldwide reconsidered their approach to post-market safety. Many regulators have since adopted a life-cycle approach to regulation of medicines, facilitating faster approval of new medicines while recogn... (Source: SafetyLit)
Source: SafetyLit - August 14, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Vioxx, Once Vilified Like Thalidomide, May Also Return To The Market
Obviously, the FDA would want to be certain that the benefit for using Vioxx in hemophilic arthropathy outweighed the attendant risk before allowing Vioxx (rofecoxib) to be reintroduced to the marketplace. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 10, 2019 Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news
Drug Withdrawn - Vioxx, A Perspective After National Arthritis Meeting
Title: Drug Withdrawn - Vioxx, A Perspective After National Arthritis MeetingCategory: Doctor's& Expert's views on SymptomsCreated: 11/1/2004 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:10 PM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 13, 2018 Category: Rheumatology Source Type: news
Shocker! Is Vioxx Coming Back... as an Orphan Drug?
(MedPage Today) -- Milton Packer wonders whether its return represents innovation or opportunism (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 2, 2018 Category: Psychiatry Source Type: news
Cambridge biotech startup seeking to repurpose Vioxx raises $5M
Tremeau Pharmaceuticals, a Cambridge biotech startup that is seeking to repurpose the controversial Merck& Co. arthritis drug Vioxx as a treatment for joint pain caused by hemophilia, has closed its first equity round.
Tremeau, which was founded last year, announced Thursday that it has raised $5.2 million in equity financing, although it did not disclose the investors that participated. The six-employee company said the funding would be used to advance the drug — whose generic name is rofecoxib… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 15, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
Usual Suspects: Lawyers Used To Getting Their Way In MDL Process To Lead Opioid Litigation
The prospect of the biggest payday since the $200 billion tobacco settlement in 1998 has drawn many of the same plaintiff lawyers who appear again and again in big tort cases over everything from VW diesels to Vioxx to the BP Deepwater Horizon disaster. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 23, 2018 Category: Pharmaceuticals Authors: Legal Newsline, Contributor Source Type: news
Startup wants to bring back Vioxx for hemophilia joint pain
A tiny pharmaceutical company is trying to bring back the arthritis pill Vioxx but for patients with a bleeding disorder (Source: ABC News: Health)
Source: ABC News: Health - November 21, 2017 Category: Consumer Health News Tags: Health Source Type: news
The Latest: Startup could bring back Vioxx for hemophilia
A tiny pharmaceutical company is trying to bring back the arthritis pill Vioxx but for patients with a bleeding disorder (Source: ABC News: Health)
Source: ABC News: Health - November 21, 2017 Category: Consumer Health News Tags: Health Source Type: news
A Vioxx comeback? A startup eyes the drug for hemophilia
The blockbuster drug was pulled in 2004 amid health concerns, but it may find a second life as a hemophilia treatment (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 21, 2017 Category: Consumer Health News Source Type: news
APNewsbreak: Startup could bring back Vioxx for hemophilia
A tiny pharmaceutical company is trying to bring back the arthritis pill Vioxx but for patients with a bleeding disorder (Source: ABC News: Health)
Source: ABC News: Health - November 21, 2017 Category: Consumer Health News Tags: Health Source Type: news
rofecoxib, Vioxx
Title: rofecoxib, VioxxCategory: MedicationsCreated: 10/14/1999 12:00:00 AMLast Editorial Review: 8/8/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - August 8, 2017 Category: Rheumatology Source Type: news
Ibuprofen linked to increased risk of heart attacks
Conclusion
This study is a useful addition to our knowledge about the links between NSAIDs and heart attack risk. The study suggests all commonly-used NSAIDs are linked to a similarly-raised risk of heart attacks, that the risk generally rises with the dose, and that it is highest in the first month of treatment.
The researchers did a good job at taking account of potential confounding factors that could have affected the results. Even so, we don't know for sure that the NSAIDs were the direct cause of the problem. For example, if you are prescribed NSAIDs for a painful condition, and have a heart attack two weeks later, i...
Source: NHS News Feed - May 10, 2017 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
